Guobang Pharma Ltd Working Capital to Net Assets Ratio
Guobang Pharma Ltd working capital to net assets ratio. Guobang Pharma Ltd (605507) has a Working Capital to Net Assets ratio of 44.0% as of June 2026. Working capital of CN¥3.70 Billion (current assets of CN¥6.47 Billion minus current liabilities of CN¥2.77 Billion) is measured against net assets of CN¥8.40 Billion. A higher ratio indicates strong short-term liquidity financed by the equity base. Check tangible equity quality of Guobang Pharma Ltd to evaluate the tangible quality of the company's equity base.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
Working Capital to Net Assets Ratio of Guobang Pharma Ltd (2017–2025)
Working capital to net assets ratio of Guobang Pharma Ltd from 2017 to 2025. This chart shows how Guobang Pharma Ltd's Working Capital to Net Assets ratio has evolved across 9 annual periods from 2017 to 2025. As of June 2026, the ratio stands at 44.0%, reflecting working capital of CN¥3.70 Billion against net assets of CN¥8.40 Billion CNY. See Guobang Pharma Ltd (605507) defensive interval to measure how many days the company can operate on defensive assets alone.
Guobang Pharma Ltd Working Capital to Net Assets Ratio by Year (2017–2025)
Guobang Pharma Ltd working capital to net assets ratio by year from 2017 to 2025. The table below presents the year-by-year Working Capital to Net Assets ratio for Guobang Pharma Ltd from 2017 to 2025, covering 9 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. For the complete balance sheet picture, see 605507 current and non-current assets.
| Year | WC/NA Ratio | Working Capital (CNY) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2025 | 49.0% | CN¥4.19 Billion | CN¥8.56 Billion | CN¥6.11 Billion | CN¥1.92 Billion | ▲ +7.8 pp |
| 2024 | 41.2% | CN¥3.32 Billion | CN¥8.05 Billion | CN¥5.87 Billion | CN¥2.56 Billion | ▲ +0.9 pp |
| 2023 | 40.3% | CN¥2.99 Billion | CN¥7.44 Billion | CN¥5.44 Billion | CN¥2.45 Billion | ▼ -5.4 pp |
| 2022 | 45.7% | CN¥3.27 Billion | CN¥7.15 Billion | CN¥5.13 Billion | CN¥1.86 Billion | ▼ -8.1 pp |
| 2021 | 53.8% | CN¥3.41 Billion | CN¥6.35 Billion | CN¥4.57 Billion | CN¥1.15 Billion | ▲ +26.3 pp |
| 2020 | 27.4% | CN¥898.70 Million | CN¥3.27 Billion | CN¥2.87 Billion | CN¥1.97 Billion | ▼ -17.9 pp |
| 2019 | 45.4% | CN¥1.19 Billion | CN¥2.62 Billion | CN¥2.76 Billion | CN¥1.57 Billion | ▲ +2.3 pp |
| 2018 | 43.1% | CN¥1.12 Billion | CN¥2.59 Billion | CN¥2.83 Billion | CN¥1.72 Billion | ▲ +15.3 pp |
| 2017 | 27.8% | CN¥613.21 Million | CN¥2.21 Billion | CN¥2.43 Billion | CN¥1.81 Billion | — |